Hospira S.p.A.

FDA inspection history across 2 sites, 2014 to 2022

2
Form 483s
2
Warning letters
1
Close-out

Every document, by year

  • Form 483
  • Close-out
  • Warning letter

2014: one Form 483; 2015: two warning letters; 2017: one close-out letter; 2022: one amended 483.

The story so far

Built from the dates and citations on the documents themselves.

  1. 2014–17Two warning letters, one Form 483 and one close-out letter, at Liscate, Italy and Lake Forest, Illinois.
  2. 2014The longest 483 on file: 10 observations over 7 pages at Liscate, Italy.
  3. 2022One amended 483, at Liscate, Italy.

Cited most

Across all Hospira S.p.A. observations on file

The complete Hospira S.p.A. file.

All 5 documents as original PDFs, in one order. For supplier audits, diligence and inspection prep.

$421$495

15% off buying them one by one

Sites

Documents

5 on file, newest first
DateDocumentPrice
2022-12-06Amended 483 Amended 483$99
2017-06-13Close-out Close-out letter$99
2015-03-31Warning letter Warning letter$99
2015-03-31Warning letter Warning letter$99
2014-05-13483 Form 483$99

Investigators on these documents

William Leonard (1)

FEI number 3004640070 · most recent document Dec 6, 2022

About Hospira S.p.A.

How many FDA Form 483s has Hospira S.p.A. received?

FDA Intel has 2 Form 483s on file for Hospira S.p.A.; the most recent is dated Dec 6, 2022.

When was Hospira S.p.A. last inspected by FDA?

The most recent FDA inspection document on file for Hospira S.p.A. is a Form 483 dated Dec 6, 2022, for the site in Liscate, Italy.

What did FDA cite at Hospira S.p.A.?

The regulations cited most in the observations on file for Hospira S.p.A. are 21 CFR 211.42 (Design and construction features), 3 times; 21 CFR 211.160(a) (General requirements), 2 times; 21 CFR 211.192 (Production record review), 2 times.

Has Hospira S.p.A. received an FDA warning letter?

Yes. FDA Intel has 2 FDA warning letters on file for Hospira S.p.A.; the most recent is dated Mar 31, 2015.

Hospira S.p.A. FDA Inspection History & 483s · FDA Intel